medicaid glp-1 What to Know About the BALANCE Model for GLP-1s in Medicare and and the Medicare Bridge Did you know? Approximately 36%

10.1056/NEJM199807233390404

Vomiting occurs in approximately 24% of Wegovy users, though it is generally less common than nausea and tends to correlate with nausea severity

Concurrently, patients also experienced sustained weight loss of 2.33.0 kg ( p 0.015 vs

2 Patients should be advised about the signs and symptoms of pancreatitis, even though this adverse event is considered to be rare

Hanna, M., Jaqua, E., Nguyen, V., & Clay, J

In general, without knowing what Medicaid and Medicare generally are currently paying for these drugs on net, it is uncertain whether the lower prices that will be made available to state Medicaid programs and Part D plans under the BALANCE Model for currently covered uses of GLP-1s will generate enough savings to offset the additional costs from expanded use of these medications for obesity